Puma Biotechnology Inc PBYI.OQ PBYI.O is expected to show a rise in quarterly revenue when it reports results on February 26 for the period ending December 31 2025
The Los Angeles California-based company is expected to report a 16.1% increase in revenue to $68.6 million from $59.1 million a year ago, according to the estimate from one analyst, based on LSEG data.The company's guidance on November 6 2025, for the period ended December 31, was for revenue between $67.00 million and $70.00 million.
LSEG's mean analyst estimate for Puma Biotechnology Inc is for earnings of 23 cents per share.
The one available analyst rating on the shares is "hold".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Puma Biotechnology Inc is $5.00, about 29.7% below its last closing price of $7.11
This summary was machine generated February 24 at 21:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments